APO Research
Talk to an analyst

APO RESEARCH · REPORT

PCSK9 Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global PCSK9 Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025195 pages

Choose your research edition.

Industry ResearchPCSK9 Antagonists Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal PCSK9 Antagonists Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal PCSK9 Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PCSK9 Antagonists Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal PCSK9 Antagonists Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global PCSK9 Antagonists market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for PCSK9 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of PCSK9 Antagonists include Amgen, Merck, Novartis, Regeneron Pharmaceuticals, Sanofi, Hasten Biopharmaceutical, Jiangsu Hengrui Pharmaceuticals, Junshi Biosciences and Akeso, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PCSK9 Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PCSK9 Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PCSK9 Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PCSK9 Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

PCSK9 Antagonists Segment by Company

Amgen

Merck

Novartis

Regeneron Pharmaceuticals

Sanofi

Hasten Biopharmaceutical

Jiangsu Hengrui Pharmaceuticals

Junshi Biosciences

Akeso

Innovent Biologics

Salubris Pharmaceuticals

PCSK9 Antagonists Segment by Type

Monoclonal Antibody

siRNA

Other

PCSK9 Antagonists Segment by Application

Atherosclerotic Cardiovascular Disease

Hypercholesterolemia

Others

PCSK9 Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PCSK9 Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PCSK9 Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PCSK9 Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PCSK9 Antagonists market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of PCSK9 Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of PCSK9 Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of PCSK9 Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. PCSK9 Antagonists Industry Trends Table 2. PCSK9 Antagonists Industry Drivers Table 3. PCSK9 Antagonists Industry Opportunities and Challenges Table 4. PCSK9 Antagonists Industry Restraints Table 5. Global PCSK9 Antagonists Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global PCSK9 Antagonists Revenue Market Share by Manufacturers (2021-2026) Table 7. Global PCSK9 Antagonists Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global PCSK9 Antagonists Sales Market Share by Manufacturers Table 9. Global PCSK9 Antagonists Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global PCSK9 Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global PCSK9 Antagonists Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global PCSK9 Antagonists Manufacturers, Product Type & Application Table 13. Global PCSK9 Antagonists Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global PCSK9 Antagonists by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Monoclonal Antibody Table 17. Major Manufacturers of siRNA Table 18. Major Manufacturers of Other Table 19. Global PCSK9 Antagonists Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global PCSK9 Antagonists Sales by Type (2021-2026) & (K Units) Table 21. Global PCSK9 Antagonists Sales by Type (2027-2032) & (K Units) Table 22. Global PCSK9 Antagonists Sales Market Share by Type (2021-2026) Table 23. Global PCSK9 Antagonists Sales Market Share by Type (2027-2032) Table 24. Global PCSK9 Antagonists Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global PCSK9 Antagonists Revenue by Type (2021-2026) & (K Units) Table 26. Global PCSK9 Antagonists Revenue by Type (2027-2032) & (K Units) Table 27. Global PCSK9 Antagonists Revenue Market Share by Type (2021-2026) Table 28. Global PCSK9 Antagonists Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Atherosclerotic Cardiovascular Disease Table 30. Major Manufacturers of Hypercholesterolemia Table 31. Major Manufacturers of Others Table 32. Global PCSK9 Antagonists Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global PCSK9 Antagonists Sales by Application (2021-2026) & (K Units) Table 34. Global PCSK9 Antagonists Sales by Application (2027-2032) & (K Units) Table 35. Global PCSK9 Antagonists Sales Market Share by Application (2021-2026) Table 36. Global PCSK9 Antagonists Sales Market Share by Application (2027-2032) Table 37. Global PCSK9 Antagonists Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global PCSK9 Antagonists Revenue by Application (2021-2026) & (K Units) Table 39. Global PCSK9 Antagonists Revenue by Application (2027-2032) & (K Units) Table 40. Global PCSK9 Antagonists Revenue Market Share by Application (2021-2026) Table 41. Global PCSK9 Antagonists Revenue Market Share by Application (2027-2032) Table 42. Global PCSK9 Antagonists Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global PCSK9 Antagonists Sales by Region (2021-2026) & (K Units) Table 44. Global PCSK9 Antagonists Sales Market Share by Region (2021-2026) Table 45. Global PCSK9 Antagonists Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global PCSK9 Antagonists Sales Forecasted Market Share by Region (2027-2032) Table 47. North America PCSK9 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America PCSK9 Antagonists Sales by Country (2021-2026) & (K Units) Table 49. North America PCSK9 Antagonists Sales by Country (2027-2032) & (K Units) Table 50. Europe PCSK9 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe PCSK9 Antagonists Sales by Country (2021-2026) & (K Units) Table 52. Europe PCSK9 Antagonists Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific PCSK9 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific PCSK9 Antagonists Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific PCSK9 Antagonists Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa PCSK9 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa PCSK9 Antagonists Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa PCSK9 Antagonists Sales by Country (2027-2032) & (K Units) Table 59. Global PCSK9 Antagonists Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global PCSK9 Antagonists Revenue by Region (2021-2026) & (US$ Million) Table 61. Global PCSK9 Antagonists Revenue by Region (2027-2032) & (US$ Million) Table 62. Global PCSK9 Antagonists Revenue Market Share by Region (2021-2026) Table 63. Global PCSK9 Antagonists Revenue Market Share by Region (2027-2032) Table 64. Amgen Company Information Table 65. Amgen Business Overview Table 66. Amgen PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Amgen PCSK9 Antagonists Product Portfolio Table 68. Amgen Recent Development Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Merck PCSK9 Antagonists Product Portfolio Table 73. Merck Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis PCSK9 Antagonists Product Portfolio Table 78. Novartis Recent Development Table 79. Regeneron Pharmaceuticals Company Information Table 80. Regeneron Pharmaceuticals Business Overview Table 81. Regeneron Pharmaceuticals PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Regeneron Pharmaceuticals PCSK9 Antagonists Product Portfolio Table 83. Regeneron Pharmaceuticals Recent Development Table 84. Sanofi Company Information Table 85. Sanofi Business Overview Table 86. Sanofi PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Sanofi PCSK9 Antagonists Product Portfolio Table 88. Sanofi Recent Development Table 89. Hasten Biopharmaceutical Company Information Table 90. Hasten Biopharmaceutical Business Overview Table 91. Hasten Biopharmaceutical PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Hasten Biopharmaceutical PCSK9 Antagonists Product Portfolio Table 93. Hasten Biopharmaceutical Recent Development Table 94. Jiangsu Hengrui Pharmaceuticals Company Information Table 95. Jiangsu Hengrui Pharmaceuticals Business Overview Table 96. Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Product Portfolio Table 98. Jiangsu Hengrui Pharmaceuticals Recent Development Table 99. Junshi Biosciences Company Information Table 100. Junshi Biosciences Business Overview Table 101. Junshi Biosciences PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Junshi Biosciences PCSK9 Antagonists Product Portfolio Table 103. Junshi Biosciences Recent Development Table 104. Akeso Company Information Table 105. Akeso Business Overview Table 106. Akeso PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Akeso PCSK9 Antagonists Product Portfolio Table 108. Akeso Recent Development Table 109. Innovent Biologics Company Information Table 110. Innovent Biologics Business Overview Table 111. Innovent Biologics PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Innovent Biologics PCSK9 Antagonists Product Portfolio Table 113. Innovent Biologics Recent Development Table 114. Salubris Pharmaceuticals Company Information Table 115. Salubris Pharmaceuticals Business Overview Table 116. Salubris Pharmaceuticals PCSK9 Antagonists Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Salubris Pharmaceuticals PCSK9 Antagonists Product Portfolio Table 118. Salubris Pharmaceuticals Recent Development Table 119. Key Raw Materials Table 120. Raw Materials Key Suppliers Table 121. PCSK9 Antagonists Distributors List Table 122. PCSK9 Antagonists Customers List Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources Table 126. Primary Sources List of Figures Figure 1. PCSK9 Antagonists Product Image Figure 2. Global PCSK9 Antagonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PCSK9 Antagonists Market Size (2021-2032) & (US$ Million) Figure 4. Global PCSK9 Antagonists Sales (2021-2032) & (K Units) Figure 5. Global PCSK9 Antagonists Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 PCSK9 Antagonists Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Monoclonal Antibody Image Figure 9. siRNA Image Figure 10. Other Image Figure 11. Global PCSK9 Antagonists Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global PCSK9 Antagonists Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global PCSK9 Antagonists Sales Market Share by Type (2021-2032) Figure 14. Global PCSK9 Antagonists Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global PCSK9 Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global PCSK9 Antagonists Revenue Market Share by Type (2021-2032) Figure 17. Atherosclerotic Cardiovascular Disease Image Figure 18. Hypercholesterolemia Image Figure 19. Others Image Figure 20. Global PCSK9 Antagonists Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global PCSK9 Antagonists Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global PCSK9 Antagonists Sales Market Share by Application (2021-2032) Figure 23. Global PCSK9 Antagonists Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global PCSK9 Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global PCSK9 Antagonists Revenue Market Share by Application (2021-2032) Figure 26. North America PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America PCSK9 Antagonists Sales Market Share by Country (2021-2032) Figure 28. U.S. PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe PCSK9 Antagonists Sales Market Share by Country (2021-2032) Figure 33. Germany PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific PCSK9 Antagonists Sales Market Share by Country (2021-2032) Figure 40. China PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa PCSK9 Antagonists Sales Market Share by Country (2021-2032) Figure 48. Brazil PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile PCSK9 Antagonists Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global PCSK9 Antagonists Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global PCSK9 Antagonists Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America PCSK9 Antagonists Revenue (2021-2032) & (US$ Million) Figure 59. North America PCSK9 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe PCSK9 Antagonists Revenue (2021-2032) & (US$ Million) Figure 61. Europe PCSK9 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific PCSK9 Antagonists Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific PCSK9 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa PCSK9 Antagonists Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa PCSK9 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. PCSK9 Antagonists Value Chain Figure 67. Manufacturing Cost Structure Figure 68. PCSK9 Antagonists Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibody
  • siRNA
  • Other
Applications
  • Atherosclerotic Cardiovascular Disease
  • Hypercholesterolemia
  • Others
Companies covered
  • Amgen
  • Merck
  • Novartis
  • Regeneron Pharmaceuticals
  • Sanofi
  • Hasten Biopharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Junshi Biosciences
  • Akeso
  • Innovent Biologics
  • Salubris Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global PCSK9 Antagonists Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global PCSK9 Antagonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global PCSK9 Antagonists Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global PCSK9 Antagonists Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global PCSK9 Antagonists Market Dynamics
  1. 2.1 PCSK9 Antagonists Industry Trends
  2. 2.2 PCSK9 Antagonists Industry Drivers
  3. 2.3 PCSK9 Antagonists Industry Opportunities and Challenges
  4. 2.4 PCSK9 Antagonists Industry Restraints
3 PCSK9 Antagonists Market by Manufacturers
  1. 3.1 Global PCSK9 Antagonists Revenue by Manufacturers (2021-2026)
  2. 3.2 Global PCSK9 Antagonists Sales by Manufacturers (2021-2026)
  3. 3.3 Global PCSK9 Antagonists Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global PCSK9 Antagonists Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global PCSK9 Antagonists Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global PCSK9 Antagonists Manufacturers, Product Type & Application
  7. 3.7 Global PCSK9 Antagonists Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global PCSK9 Antagonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 PCSK9 Antagonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 PCSK9 Antagonists Tier 1, Tier 2, and Tier 3
4 PCSK9 Antagonists Market by Type
  1. 4.1 PCSK9 Antagonists Type Introduction
  2. 4.1.1 Monoclonal Antibody
  3. 4.1.2 siRNA
  4. 4.1.3 Other
  5. 4.2 Global PCSK9 Antagonists Sales by Type
  6. 4.2.1 Global PCSK9 Antagonists Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global PCSK9 Antagonists Sales by Type (2021-2032)
  8. 4.2.3 Global PCSK9 Antagonists Sales Market Share by Type (2021-2032)
  9. 4.3 Global PCSK9 Antagonists Revenue by Type
  10. 4.3.1 Global PCSK9 Antagonists Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global PCSK9 Antagonists Revenue by Type (2021-2032)
  12. 4.3.3 Global PCSK9 Antagonists Revenue Market Share by Type (2021-2032)
5 PCSK9 Antagonists Market by Application
  1. 5.1 PCSK9 Antagonists Application Introduction
  2. 5.1.1 Atherosclerotic Cardiovascular Disease
  3. 5.1.2 Hypercholesterolemia
  4. 5.1.3 Others
  5. 5.2 Global PCSK9 Antagonists Sales by Application
  6. 5.2.1 Global PCSK9 Antagonists Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global PCSK9 Antagonists Sales by Application (2021-2032)
  8. 5.2.3 Global PCSK9 Antagonists Sales Market Share by Application (2021-2032)
  9. 5.3 Global PCSK9 Antagonists Revenue by Application
  10. 5.3.1 Global PCSK9 Antagonists Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global PCSK9 Antagonists Revenue by Application (2021-2032)
  12. 5.3.3 Global PCSK9 Antagonists Revenue Market Share by Application (2021-2032)
6 Global PCSK9 Antagonists Sales by Region
  1. 6.1 Global PCSK9 Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PCSK9 Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global PCSK9 Antagonists Sales by Region (2021-2026)
  4. 6.2.2 Global PCSK9 Antagonists Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America PCSK9 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America PCSK9 Antagonists Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe PCSK9 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe PCSK9 Antagonists Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific PCSK9 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific PCSK9 Antagonists Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa PCSK9 Antagonists Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa PCSK9 Antagonists Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global PCSK9 Antagonists Revenue by Region
  1. 7.1 Global PCSK9 Antagonists Revenue by Region
  2. 7.1.1 Global PCSK9 Antagonists Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global PCSK9 Antagonists Revenue by Region (2021-2026)
  4. 7.1.3 Global PCSK9 Antagonists Revenue by Region (2027-2032)
  5. 7.1.4 Global PCSK9 Antagonists Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America PCSK9 Antagonists Revenue (2021-2032)
  8. 7.2.2 North America PCSK9 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe PCSK9 Antagonists Revenue (2021-2032)
  11. 7.3.2 Europe PCSK9 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific PCSK9 Antagonists Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific PCSK9 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa PCSK9 Antagonists Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa PCSK9 Antagonists Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Amgen
  2. 8.1.1 Amgen Company Information
  3. 8.1.2 Amgen Business Overview
  4. 8.1.3 Amgen PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Amgen PCSK9 Antagonists Product Portfolio
  6. 8.1.5 Amgen Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck PCSK9 Antagonists Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis PCSK9 Antagonists Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Regeneron Pharmaceuticals
  20. 8.4.1 Regeneron Pharmaceuticals Company Information
  21. 8.4.2 Regeneron Pharmaceuticals Business Overview
  22. 8.4.3 Regeneron Pharmaceuticals PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Regeneron Pharmaceuticals PCSK9 Antagonists Product Portfolio
  24. 8.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi PCSK9 Antagonists Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Hasten Biopharmaceutical
  32. 8.6.1 Hasten Biopharmaceutical Company Information
  33. 8.6.2 Hasten Biopharmaceutical Business Overview
  34. 8.6.3 Hasten Biopharmaceutical PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hasten Biopharmaceutical PCSK9 Antagonists Product Portfolio
  36. 8.6.5 Hasten Biopharmaceutical Recent Developments
  37. 8.7 Jiangsu Hengrui Pharmaceuticals
  38. 8.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
  39. 8.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  40. 8.7.3 Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Hengrui Pharmaceuticals PCSK9 Antagonists Product Portfolio
  42. 8.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  43. 8.8 Junshi Biosciences
  44. 8.8.1 Junshi Biosciences Company Information
  45. 8.8.2 Junshi Biosciences Business Overview
  46. 8.8.3 Junshi Biosciences PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Junshi Biosciences PCSK9 Antagonists Product Portfolio
  48. 8.8.5 Junshi Biosciences Recent Developments
  49. 8.9 Akeso
  50. 8.9.1 Akeso Company Information
  51. 8.9.2 Akeso Business Overview
  52. 8.9.3 Akeso PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Akeso PCSK9 Antagonists Product Portfolio
  54. 8.9.5 Akeso Recent Developments
  55. 8.10 Innovent Biologics
  56. 8.10.1 Innovent Biologics Company Information
  57. 8.10.2 Innovent Biologics Business Overview
  58. 8.10.3 Innovent Biologics PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Innovent Biologics PCSK9 Antagonists Product Portfolio
  60. 8.10.5 Innovent Biologics Recent Developments
  61. 8.11 Salubris Pharmaceuticals
  62. 8.11.1 Salubris Pharmaceuticals Company Information
  63. 8.11.2 Salubris Pharmaceuticals Business Overview
  64. 8.11.3 Salubris Pharmaceuticals PCSK9 Antagonists Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Salubris Pharmaceuticals PCSK9 Antagonists Product Portfolio
  66. 8.11.5 Salubris Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PCSK9 Antagonists Value Chain Analysis
  2. 9.1.1 PCSK9 Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PCSK9 Antagonists Production Mode & Process
  6. 9.2 PCSK9 Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PCSK9 Antagonists Distributors
  9. 9.2.3 PCSK9 Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst